These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 30885900)

  • 1. Ibalizumab, a Novel Monoclonal Antibody for the Management of Multidrug-Resistant HIV-1 Infection.
    Beccari MV; Mogle BT; Sidman EF; Mastro KA; Asiago-Reddy E; Kufel WD
    Antimicrob Agents Chemother; 2019 Jun; 63(6):. PubMed ID: 30885900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety, pharmacokinetics, and antiretroviral activity of multiple doses of ibalizumab (formerly TNX-355), an anti-CD4 monoclonal antibody, in human immunodeficiency virus type 1-infected adults.
    Jacobson JM; Kuritzkes DR; Godofsky E; DeJesus E; Larson JA; Weinheimer SP; Lewis ST
    Antimicrob Agents Chemother; 2009 Feb; 53(2):450-7. PubMed ID: 19015347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody-based strategies in HIV therapy.
    Kufel WD
    Int J Antimicrob Agents; 2020 Dec; 56(6):106186. PubMed ID: 33045349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ibalizumab for the treatment of multidrug-resistant HIV-1 infection.
    Rizza SA; Bhatia R; Zeuli J; Temesgen Z
    Drugs Today (Barc); 2019 Jan; 55(1):25-34. PubMed ID: 30740610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 3 Study of Ibalizumab for Multidrug-Resistant HIV-1.
    Emu B; Fessel J; Schrader S; Kumar P; Richmond G; Win S; Weinheimer S; Marsolais C; Lewis S
    N Engl J Med; 2018 Aug; 379(7):645-654. PubMed ID: 30110589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ibalizumab: A Review in Multidrug-Resistant HIV-1 Infection.
    Blair HA
    Drugs; 2020 Feb; 80(2):189-196. PubMed ID: 31970712
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ibalizumab: The First Monoclonal Antibody for the Treatment of HIV-1 Infection.
    Chahine EB; Durham SH
    Ann Pharmacother; 2021 Feb; 55(2):230-239. PubMed ID: 32659101
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of asparagine-linked glycosylation sites in variable region 5 of human immunodeficiency virus type 1 envelope is associated with resistance to CD4 antibody ibalizumab.
    Toma J; Weinheimer SP; Stawiski E; Whitcomb JM; Lewis ST; Petropoulos CJ; Huang W
    J Virol; 2011 Apr; 85(8):3872-80. PubMed ID: 21289125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ibalizumab.
    Bettiker RL; Koren DE; Jacobson JM
    Curr Opin HIV AIDS; 2018 Jul; 13(4):354-358. PubMed ID: 29746266
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-CD4 monoclonal antibody ibalizumab exhibits breadth and potency against HIV-1, with natural resistance mediated by the loss of a V5 glycan in envelope.
    Pace CS; Fordyce MW; Franco D; Kao CY; Seaman MS; Ho DD
    J Acquir Immune Defic Syndr; 2013 Jan; 62(1):1-9. PubMed ID: 23023102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ibalizumab and Fostemsavir in the Management of Heavily Pre-Treated HIV-infected Patients.
    Riccardi N; Berruti M; Del Puente F; Taramasso L; Di Biagio A
    Recent Pat Antiinfect Drug Discov; 2018; 13(3):190-197. PubMed ID: 30378502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strategic addition of an N-linked glycan to a monoclonal antibody improves its HIV-1-neutralizing activity.
    Song R; Oren DA; Franco D; Seaman MS; Ho DD
    Nat Biotechnol; 2013 Nov; 31(11):1047-52. PubMed ID: 24097413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy, Pharmacokinetics, and Safety Over 48 Weeks With Ibalizumab-Based Therapy in Treatment-Experienced Adults Infected With HIV-1: A Phase 2a Study.
    Gathe JC; Hardwicke RL; Garcia F; Weinheimer S; Lewis ST; Cash RB
    J Acquir Immune Defic Syndr; 2021 Apr; 86(4):482-489. PubMed ID: 33427765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epitope mapping of ibalizumab, a humanized anti-CD4 monoclonal antibody with anti-HIV-1 activity in infected patients.
    Song R; Franco D; Kao CY; Yu F; Huang Y; Ho DD
    J Virol; 2010 Jul; 84(14):6935-42. PubMed ID: 20463063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ex vivo sensitivity to broadly neutralizing antibodies and anti-CD4 antibody UB-421 of infectious viral isolates from people living with multidrug-resistant HIV.
    Rai MA; Blazkova J; Justement JS; Shi V; Kennedy BD; Manning MR; McLaughlin M; Sneller MC; Pau AK; Moir S; Chun TW
    EBioMedicine; 2024 Jun; 104():105151. PubMed ID: 38728839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ibalizumab: First Global Approval.
    Markham A
    Drugs; 2018 May; 78(7):781-785. PubMed ID: 29675744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Cost-Effectiveness and Budget Impact of Ibalizumab-uiyk for Adults with Multidrug-Resistant HIV-1 Infection in the United States.
    Brogan AJ; Talbird SE; Davis AE; La EM; Kumar PN
    Pharmacoeconomics; 2021 Apr; 39(4):421-432. PubMed ID: 33532919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ibalizumab: an anti-CD4 monoclonal antibody for the treatment of HIV-1 infection.
    Bruno CJ; Jacobson JM
    J Antimicrob Chemother; 2010 Sep; 65(9):1839-41. PubMed ID: 20639524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ibalizumab shows in-vitro activity against group A and group B HIV-2 clinical isolates.
    Le Hingrat Q; Collin G; Bachelard A; Ghosn J; Chalal S; Pacanowski J; Peytavin G; Weinheimer S; Marsolais C; Damond F; Matheron S; Charpentier C; Descamps D;
    AIDS; 2022 Jul; 36(8):1055-1060. PubMed ID: 35262531
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ibalizumab, a CD4-specific mAb to inhibit HIV-1 infection.
    Dimitrov A
    Curr Opin Investig Drugs; 2007 Aug; 8(8):653-61. PubMed ID: 17668367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.